MAP4K4-IN-3

• Description:

  MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. Antidiabetic agent[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  MAP4K

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/map4k4-in-3.html

• Purity:

  99.15

• Solubility:

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  NC1=NC=C(C2=CC(C3=CC=C(Cl)C=C3)=C(N)N=C2)C=N1

• Molecular Formula:

  C15H12ClN5

• Molecular Weight:

  297.74

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Ammirati M, et al. Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based AntidiabeticTreatment. ACS Med Chem Lett. 2015 Oct 6;6 (11) :1128-33.|[2]Dow RL, et al. 2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety. J Med Chem. 2018 Apr 12;61 (7) :3114-3125.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  MAP4K4/HGK

• CAS Number:

  [1811510-58-3]